Conexeu Sciences Inc.
CNXU
Positions held
Your positionsCNXU isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $115.65M | Enterprise value | $95.80M | Trailing P/E | — | Forward P/E | -7.74 |
| PEG | — | Price / book | 11.92 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.3% | ROA | -1.7% | Debt / equity | 0.08 |
| Current ratio | 5.31 | Free cash flow | -$5.40M | Analyst recommendation | none | Mean target | $20.00 |
| 52w high | $18.79 | 52w low | $3.05 |
Quarterly
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$7.7M | -$2.3M | -$1.7M | -$1.9M | -$1.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.7M | -$2.4M | -$1.7M | -$1.9M | -$1.3M | — |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$3.9M | -$0.5M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$4.0M | -$0.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
2026-09-01 · Conexeu Sciences Sets September and October 2026 Conference Schedule
2026-08-18 · Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
2026-08-03 · Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
2026-07-14 · The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
Price (daily)
Full chart · RSI · MACD · patterns